A biosimilar to Eli Lilly’s Forsteo, biosimilar teriparatide, has been launched across Europe by Gedeon Richter following the patent expiration of the reference product.
A biosimilar to Eli Lilly’s Forsteo, biosimilar teriparatide, has been launched across Europe by Gedeon Richter following the patent expiration of the reference product, it was revealed in an Aug. 20, 2019 press release.
The biosimilar will be marketed as Terrosa in Europe and has already achieved regulatory approval for the same indications as the reference product in January 2017 by the European Commission. The therapy is indicated for use in the treatment of osteoporosis in postmenopausal women, men at increased risk of fracture, and also as associated treatment with sustained systemic glucocorticoid therapy in patients (men and women) at risk of fracture.
“We are excited about the introduction of Terrosa, our first own-developed biosimilar product in Europe, as it reflects our commitment to scientific programs linked to complex medications such as biologicals,” said Gábor Orbán, chief executive officer of Richter. “Biosimilars will increase choice and access for patients in the European countries, while providing potential cost savings to healthcare systems. We look forward to bringing more high quality and affordable biosimilar products to the market.”
Source:
